Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease
Author: ["Edith Passage","Jean Chrétien Norreel","Pauline Noack-Fraissignes","Véronique Sanguedolce","Josette Pizant","Xavier Thirion","Andrée Robaglia-Schlupp","Jean François Pellissier","Michel Fontés"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Charcot-Marie-Tooth disease (CMT) is the most common hereditary peripheral neuropathy, affecting 1 in 2,500 people. The only treatment currently available is rehabilitation or corrective surgery. The most frequent form of the disease, CMT-1A, involves abnormal myelination of the peripheral nerves. Here we used a mouse model of CMT-1A to test the ability of ascorbic acid, a known promoter of myelination, to correct the CMT-1A phenotype. Ascorbic acid treatment resulted in substantial amelioration of the CMT-1A phenotype, and reduced the expression of PMP22 to a level below what is necessary to induce the disease phenotype. As ascorbic acid has already been approved by the FDA for other clinical indications, it offers an immediate therapeutic possibility for patients with the disease.
Cite this article
Passage, E., Norreel, J., Noack-Fraissignes, P. et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 10, 396–401 (2004). https://doi.org/10.1038/nm1023
